Agenus

Agenus Equity

The The Equity of Agenus (AGEN) as of Oct 15, 2026 is -271.11 M USD. In the previous year, The Equity was -326.38 M USD — a change of -16.93% (higher).

Equity

-271.11 MUSD

YoY

-16.93%

Last updated:

In 2025, Agenus's equity was -271.11 M USD, a -16.93% increase from the -326.38 M USD equity in the previous year.

The Agenus Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
-174.55 M USD
Jan 1, 2019
-231.34 M USD
Jan 1, 2020
-211.50 M USD
Jan 1, 2021
47.91 M USD
Jan 1, 2022
-54.90 M USD
Jan 1, 2023
-148.38 M USD
Jan 1, 2024
-326.38 M USD
Jan 1, 2025
-271.11 M USD
The Agenus Equity history
YEAREquityYoY
-271.11 MUSD-16.93%
-326.38 MUSD+119.96%
-148.38 MUSD+170.27%
-54.90 MUSD-214.60%
47.91 MUSD-122.65%
-211.50 MUSD-8.58%
-231.34 MUSD+32.54%
-174.55 MUSD+130.22%
-75.82 MUSD+93.77%
-39.13 MUSD-155.32%
70.73 MUSD+207.27%
23.02 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Agenus Stock analysis

What does Agenus do? Agenus Inc, listed under the ticker AGEN, is a biotechnology company based in Lexington, United States. The company operates within the Health Care sector, specifically in the Biotechnology industry. Agenus Inc has a workforce of 81 employees. It went public through an IPO on February 4, 2000. The company's website is http://agenusbio.com/. Agenus Inc is engaged in the development of technologies aimed at treating cancers and infectious diseases. The company focuses on therapies that harness the immune system to combat cancer. Agenus Inc's activities include the development of antibody discovery platforms, such as Retrocyte Display, SECANT yeast display, and phage display technologies, which are used to create human antibodies. Additionally, the company is involved in the development of vaccine programs, including Prophage, AutoSynVax, and PhosPhoSynVax, as well as saponin-based vaccine adjuvants, notably QS-21 Stimulon. The company's discovery pipeline features checkpoint modulating (CPM) antibodies. Agenus Inc also works with heat shock protein (HSP)-based Prophage vaccine candidates and synthetic vaccine candidates, such as ASV and PSV. The company's headquarters are located in Lexington, Massachusetts, and it maintains a focus on advancing immuno-oncology research and development. Agenus is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Agenus's Equity

Agenus's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Agenus's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Agenus's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Agenus's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Agenus’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Agenus stock

The Equity of Agenus is -271.11 M USD in 2025.

The Equity of Agenus changed from -326.38 M USD to -271.11 M USD, representing a -16.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Agenus since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Agenus historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Agenus

All Key Metrics — Agenus